Ventripoint Diagnostics Ltd. closed the first tranche of a $350,000 private placement, raising $180,000 to support commercialization of its AI-enabled echocardiography technology, VMS+. The company also engaged More Capital as a strategic advisor and Red Cloud Securities as a market maker to enhance growth and market presence. These steps aim to expand VMS+ adoption, build partnerships, and increase awareness in cardiology and healthcare sectors. Ventripoint's technology, approved in multiple regions, offers advanced cardiac analysis compatible with existing ultrasound equipment, positioning the company for global growth in cardiovascular care.
Apple reported its strongest June quarter ever with revenue of $109.42 billion, up 16.36% year-over-year, and earnings per share of $2.02, beating expectations for the ninth consecutive quarter. Key growth drivers include a $54 billion hardware segme...
Strategy, led by Michael Saylor, purchased 4,603 Bitcoin at an average price of $80,318 each in late August 2026, increasing its total Bitcoin holdings to 845,050 BTC. This marks the company's first Bitcoin purchase in 10 weeks after selling nearly 7...
Dell Technologies and NVIDIA both reported strong AI-driven revenue growth in Q2 FY27, with Dell posting $46.97 billion revenue and NVIDIA $96.22 billion. While NVIDIA dominates as the AI compute platform owner with high margins, Dell is gaining grou...
Chevron shares have surged over 42% in 2026, approaching a 52-week high near $212. Strong Q2 earnings, production growth, and debt reduction support the rally, but the stock trades above its price target of $204.67, suggesting limited upside. Bulls p...
The Dividend Harvesting Portfolio achieved a 45.8% return on investment, generating $3,289.51 in annual dividends from a $28,800 investment, with a yield of 7.83%. Recent portfolio additions include Pfizer, valued for its yield above 6% and low earni...
